PMID- 26719012
OWN - NLM
STAT- MEDLINE
DCOM- 20160922
LR  - 20220309
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 21
DP  - 2015 Dec 31
TI  - Clinical Characteristics of Patients with Gastroesophageal Reflux Disease 
      Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg 
      Esomeprazole on Reflux Symptoms and Quality of Life.
PG  - 4111-21
AB  - BACKGROUND Refractory gastroesophageal reflux disease (GERD) may deteriorate 
      patient quality of life (QOL) despite proton pump inhibitor (PPI) therapy. 
      MATERIAL AND METHODS Nineteen Japanese institutions were surveyed to determine 
      the clinical characteristics and QOL of patients with refractory GERD. Those 
      patients treated with a conventional PPI were switched to 20 mg esomeprazole for 
      4 weeks. Symptoms and QOL were assessed using Global Overall Symptom and 
      Gastrointestinal Symptom Rating Scale (GSRS) questionnaires at baseline and at 2 
      and/or 4 weeks of esomeprazole treatment. RESULTS Of 120 patients who completed 
      the survey, 58 (48.3%) had refractory GERD. Of these, 69.0% were aged >/= 65 years, 
      79.3% were prescribed a PPI at a standard or high dose, and 22.4% were prescribed 
      a PPI together with another drug. After switching to esomeprazole, patients 
      reported significant improvements in heartburn, acid regurgitation, and excessive 
      belching at 2 weeks using a symptom diary, as well as the total score, reflux, 
      abdominal pain, and indigestion, which were assessed using the GSRS at 4 weeks. 
      CONCLUSIONS About half of Japanese patients with GERD may be refractory to 
      conventional PPIs. Their reflux-related symptoms are often severe and may impair 
      QOL. Switching to esomeprazole could be used to improve their symptoms and QOL.
FAU - Takeshima, Fuminao
AU  - Takeshima F
AD  - Department of Gastroenterology and Hepatology, Nagasaki University Hospital, 
      Nagasaki, Japan.
FAU - Hashiguchi, Keiichi
AU  - Hashiguchi K
AD  - Department of Gastroenterology and Hepatology, Nagasaki University Hospital, 
      Nagasaki, Japan.
FAU - Onitsuka, Yasunori
AU  - Onitsuka Y
AD  - Department of Internal Medicine, Onitsuka Clinic of Internal Medicine, Nagasaki, 
      Japan.
FAU - Tanigawa, Ken
AU  - Tanigawa K
AD  - Department of Gastroenterology and Hepatology, Tanigawa Clinic of Radiology and 
      Gastroenterology, Nagasaki, Japan.
FAU - Minami, Hitomi
AU  - Minami H
AD  - 0.
FAU - Matsushima, Kayoko
AU  - Matsushima K
AD  - Department of Gastroenterology and Hepatology, Nagasaki University Hospital, 
      Nagasaki, Japan.
FAU - Akazawa, Yuko
AU  - Akazawa Y
AD  - Department of Gastroenterology and Hepatology, Nagasaki University Hospital, 
      Nagasaki, Japan.
FAU - Shiozawa, Ken
AU  - Shiozawa K
AD  - 0.
FAU - Yamaguchi, Naoyuki
AU  - Yamaguchi N
AD  - Department of Gastroenterology and Hepatology, Nagasaki University Hospital, 
      Nagasaki, Japan.
FAU - Taura, Naota
AU  - Taura N
AD  - Department of Gastroenterology and Hepatology, Nagasaki University Hospital, 
      Nagasaki, Japan.
FAU - Ohnita, Ken
AU  - Ohnita K
AD  - Department of Gastroenterology and Hepatology, Nagasaki University Hospital, 
      Nagasaki, Japan.
FAU - Ichikawa, Tatsuki
AU  - Ichikawa T
AD  - 0.
FAU - Isomoto, Hajime
AU  - Isomoto H
AD  - Department of Gastroenterology and Hepatology, Nagasaki University Hospital, 
      Nagasaki, Japan.
FAU - Nakao, Kazuhiko
AU  - Nakao K
AD  - Department of Gastroenterology and Hepatology, Nagasaki University Hospital, 
      Nagasaki, Japan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151231
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Proton Pump Inhibitors)
RN  - N3PA6559FT (Esomeprazole)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Esomeprazole/*therapeutic use
MH  - Female
MH  - Gastroesophageal Reflux/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Quality of Life
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
PMC - PMC4700865
EDAT- 2016/01/01 06:00
MHDA- 2016/09/23 06:00
PMCR- 2015/12/31
CRDT- 2016/01/01 06:00
PHST- 2016/01/01 06:00 [entrez]
PHST- 2016/01/01 06:00 [pubmed]
PHST- 2016/09/23 06:00 [medline]
PHST- 2015/12/31 00:00 [pmc-release]
AID - 895346 [pii]
AID - 10.12659/msm.895346 [doi]
PST - epublish
SO  - Med Sci Monit. 2015 Dec 31;21:4111-21. doi: 10.12659/msm.895346.